Overall, although many obstacles still need to be overcome before tolerogenic cell therapy becomes a reality for vasculitis patients, autologous Tregs and ex vivo-derived MPO-loaded tolerogenic DCs offer promise to be a feasible and successful antigen-specific treatment for MPO-AAV. The gene discussed is MPO; the disease is vasculitis.